CDKN2A and urinary bladder cancer: On the protein level a meta-analysis16, including data from 17 immunohistochemistry studies with 1032 subjects, investigated the p16 expression in various disease stages and found a significant association between a low expression of p16 and recurrence-free survival in patients with all stages of bladder cancer.